![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HRCT1 |
Gene summary for HRCT1 |
![]() |
Gene information | Species | Human | Gene symbol | HRCT1 | Gene ID | 646962 |
Gene name | histidine rich carboxyl terminus 1 | |
Gene Alias | LGLL338 | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6UXD1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
646962 | HRCT1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.54e-03 | 1.68e-01 | -0.1954 |
646962 | HRCT1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.55e-03 | 4.38e-01 | -0.2196 |
646962 | HRCT1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.67e-05 | 2.82e-01 | -0.1526 |
646962 | HRCT1 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.67e-03 | 1.71e-01 | -0.1464 |
646962 | HRCT1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.41e-03 | 4.91e-01 | -0.1706 |
646962 | HRCT1 | HCC1_Meng | Human | Liver | HCC | 6.71e-32 | 9.99e-02 | 0.0246 |
646962 | HRCT1 | cirrhotic1 | Human | Liver | Cirrhotic | 3.01e-02 | 1.29e-01 | 0.0202 |
646962 | HRCT1 | S028 | Human | Liver | HCC | 9.27e-16 | 5.93e-01 | 0.2503 |
646962 | HRCT1 | S029 | Human | Liver | HCC | 2.90e-13 | 6.82e-01 | 0.2581 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HRCT1 | SNV | Missense_Mutation | c.92N>T | p.Cys31Phe | p.C31F | Q6UXD1 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD | |
HRCT1 | SNV | Missense_Mutation | c.46N>A | p.Gly16Ser | p.G16S | Q6UXD1 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.895) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
HRCT1 | deletion | In_Frame_Del | novel | c.139_141delNNN | p.Ala48del | p.A48del | Q6UXD1 | protein_coding | TCGA-KB-A93J-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |